The Treatment of Migraine is being transformed in 2018.
Migraine Masters was founded to track and broadcast the fast-paced evolution of migraine treatment. Migraine is considered one of the10 most disabling illnesses on the planet, with chronic migraine having an even more severe impact.
Here you'll find a wealth of current resources, learning opportunities, and value-building engagement through our novel Axía Merits program. Become a Migraine Master during this critical year of migraine treatment evolution.
"Inspiration exists but it has to find us working."
—Pablo Picasso
Expect to be challenged by our migraine CME.
The Fundamentals
Classify patients by migraine type and differentiate between migraine and non-migraine headaches and their treatments. Raise awareness of the limitations of step-care management models contrasting them with modern stratified care models. Review strategies for accurately assessing and diagnosing acute migraine based on migraine pathophysiology, etiology, and clinical presentation and provide patients with practical advice on triggers, diaries and self-care.
Pharmacology
Classify patients by migraine type and appreciate the significance of classification on treatment of acute attacks and prophylaxis. Understand the impact of dosage forms and delivery systems on efficacy and patient satisfaction. Summarize recent research on new investigational targets for acute migraine that have the potential to be incorporated into future standards of care. Understand the importance of minimizing and managing acute attacks to prevent progression.
Meet the Patient
Take patient demographics and characteristics into consideration with more patients when recommending migraine therapies. Describe how patient attitudes, behaviors, knowledge levels, perceptions/misperceptions and levels of activation impact care.Understand the issues involved with patient decision-making in migraine treatment.
Migraine in the MediaSphere
"People who experience frequent migraines may soon have access to a new class of drugs. 'They offer the first migraine treatment that's actually aimed at the disorder,' says Peter Goadsby, an author of one of the studies and a professor of neurology at King's College in London."
The approval of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies for migraine prevention will be one of the standout developments in the central nervous system drugs sector in 2018. Novartis and Amgen will be the first to market with Aimovig, followed by Eli Lilly and Teva Pharmaceutical Industries. Read Here.
Join the MigraineMasters™ community:
Expand your basic and clinical science knowledge, develop a deeper appreciation of the attitudes and perceptions of your migraine patients, and explore new communication opportunities that can help improve the lives of millions of people navigating migraine.
What level of Mastery will you achieve?
You'll be learning and interacting at the highest level, challenged in a competitive environment with your peers. The more you prove yourself, the higher your level of Mastery. Certain achievements are rewarded with exclusive opportunities. Every successful engagement with a MenopauseMasters.org challenge earns you mastery points called Axia-Merits™ that confer accumulative benefits and rewards. We acknowledge achievers. Time is valuable – spend yours participating in challenges and activities that are worth your investment.
The Heart of Mastery.
Mastery is a legacy that is broader than medical and clinical science. The Masters who inspire us come from all walks of life and excel in many different disciplines. That's why we celebrate Mastery in its pure form, which quite simply is the human spirit realizing its full potential. Since the days of Hippocrates, history abounds with medical exemplars who have drawn inspiration from the intersection of the arts and humanities and clinical science. You’ll meet these Masters here. You’ll hear their stories, study their accomplishments and be inspired by them – and perhaps you’ll join them as Masters.
The Migraine Patient Journey
MinipodsTM are short 10-minute podcasts on the migraine journeys of actual patients. These podcasts recount the social, psychological, and clinical experiences of migraine sufferers through their stories. This audio archive serves as both a community resource where patients can find support, as well as an experiential record that helps physicians understand migraine patients through their own words outside the constraints of a clinical setting.